Belite Bio, Inc (NASDAQ: BLTE) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 2.54% | Shs Outstand | 40.09M | Perf Week | 2.80% |
| Market Cap | 6.54B | Forward P/E | 172.15 | EPS next Y | 0.95 | Insider Trans | -5.22% | Shs Float | 18.47M | Perf Month | 6.40% |
| Enterprise Value | 6.54B | PEG | 1.19 | EPS next Q | - | Inst Own | - | Short Float | 3.28% | Perf Quarter | 4.52% |
| Income | -90.85M | P/S | 0.00 | EPS this Y | - | Inst Trans | - | Short Ratio | 6.94 | Perf Half Y | -8.57% |
| Sales | 0.00 | P/B | 8.17 | EPS next Y | 128.71% | ROA | -11.13% | Short Interest | 1.32M | Perf YTD | 1.93% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | -18.14% | 52W High | 205.15 -18.47% | Perf Year | 139.81% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -12.74% | 52W Low | 61.55 171.75% | Perf 3Y | 672.75% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 0.00% | Volatility | 2.58% 3.81% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 0.00 | EPS Y/Y TTM | -58.47% | Oper. Margin | 0.00% | ATR (14) | 6.15 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 33.71 | Sales Y/Y TTM | - | Profit Margin | 0.00% | RSI (14) | 59.94 | Recom | 2.00 |
| Dividend Gr. 3/5Y | - | Current Ratio | 33.71 | EPS Q/Q | 24.44% | SMA20 | 5.05% | Beta | 0.91 | Target Price | 212.25 |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | - | SMA50 | 9.01% | Rel Volume | 0.62 | Prev Close | 163.05 |
| Employees | 41 | LT Debt/Eq | 0.01 | Earnings | Aug 10 | SMA200 | 7.34% | Avg Volume | 203.00K | Price | 167.26 |
| IPO Date | Apr 29, 2022 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 46.45% - | Net Debt/EBITDA | 0.00 | Volume | 126,434 | Change | 2.58% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| May-26-26 | Reiterated | Mizuho | Outperform | $223 → $215 |
| May-22-26 | Reiterated | Truist Financial | $217 | |
| Mar-03-26 | Reiterated | Needham | $217 | |
| Mar-03-26 | Reiterated | HC Wainwright & Co. | Buy | $185 → $200 |
| Feb-19-26 | Reiterated | Mizuho Securities | Outperform | $194 → $223 |
| Jan-06-26 | Initiated | Morgan Stanley | Overweight | $191 |
| Dec-03-25 | Reiterated | BTIG | $187 | |
| Dec-02-25 | Reiterated | Maxim Group | Buy | $140 → $200 |
| Dec-02-25 | Upgrade | Mizuho | Neutral → Outperform | $105 → $194 |
| Dec-01-25 | Reiterated | HC Wainwright & Co. | Buy | $60 → $185 |
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | |
|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | — | — | — | |
| Gross Profit | 0 | 0 | 0 | — | — | — | |
| Selling, General and Administrative Excl. Other | 39 | 10 | 7 | — | — | — | |
| Research and Development | 45 | 30 | 25 | — | — | — | |
| Other Operating Expense | 0 | 0 | 0 | — | — | — | |
| Operating Income | -84 | -40 | -32 | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 7 | 4 | 0 | — | — | — | |
| Net Income Before Taxes | -78 | -36 | -32 | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | |
| Consolidated Net Income | -78 | -36 | -32 | — | — | — | |
| Net Income From Continuing Operations | -78 | -36 | -32 | — | — | — | |
| Net Income | -78 | -36 | -32 | — | — | — | |
| EPS (Recurring) | -2.31 | -1.18 | -1.19 | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -2.31 | -1.18 | -1.19 | — | — | — | |
| EPS (Diluted) | -2.31 | -1.18 | -1.19 | — | — | — | |
| EBITDA | -77 | -36 | -31 | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | |
| Shares Outstanding | 34 | 31 | 27 | — | — | — | |
| Market Capitalization | 5,439 | 1,956 | 1,235 | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Scholl Hendrik Peter | Chief Medical Officer | Jun 18 '26 | Sale | 145.24 | 10,000 | 1,452,436 | 15,000 | Jun 22 |
| Scholl Hendrik Peter | Chief Medical Officer | Jun 16 '26 | Sale | 140.57 | 10,000 | 1,405,729 | 25,000 | Jun 17 |
| MATA NATHAN L. | Chief Scientific Officer | May 07 '26 | Sale | 153.21 | 666 | 102,039 | 0 | May 08 |
| MATA NATHAN L. | Chief Scientific Officer | May 06 '26 | Sale | 153.84 | 1,000 | 153,840 | 666 | May 07 |
| MATA NATHAN L. | Chief Scientific Officer | May 05 '26 | Sale | 155.50 | 1,000 | 155,503 | 1,666 | May 06 |
| MATA NATHAN L. | Chief Scientific Officer | May 04 '26 | Sale | 155.64 | 1,000 | 155,635 | 2,666 | May 05 |
| MATA NATHAN L. | Chief Scientific Officer | May 01 '26 | Sale | 155.78 | 1,000 | 155,778 | 3,666 | May 04 |
| MATA NATHAN L. | Chief Scientific Officer | Apr 30 '26 | Sale | 156.97 | 1,000 | 156,972 | 4,666 | May 01 |
| MATA NATHAN L. | Chief Scientific Officer | Apr 29 '26 | Sale | 155.82 | 1,000 | 155,816 | 5,666 | Apr 30 |
| MATA NATHAN L. | Chief Scientific Officer | Apr 28 '26 | Sale | 159.16 | 1,000 | 159,162 | 6,666 | Apr 29 |
| MATA NATHAN L. | Chief Scientific Officer | Apr 27 '26 | Sale | 162.64 | 1,000 | 162,642 | 7,666 | Apr 28 |
| MATA NATHAN L. | Chief Scientific Officer | Apr 24 '26 | Sale | 159.56 | 1,000 | 159,556 | 8,666 | Apr 27 |
| MATA NATHAN L. | Chief Scientific Officer | Apr 23 '26 | Sale | 166.28 | 1,000 | 166,283 | 9,666 | Apr 24 |
| MATA NATHAN L. | Chief Scientific Officer | Apr 22 '26 | Sale | 170.38 | 1,000 | 170,384 | 10,666 | Apr 23 |
| MATA NATHAN L. | Chief Scientific Officer | Apr 21 '26 | Sale | 166.00 | 1,000 | 166,001 | 11,666 | Apr 22 |